William Blair Starts Avalanche Biotechnologies (AAVL) at Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/13/2026
- Wall Street ends higher as investors turn to earnings season
- Oil prices settle lower on hopes for smoother shipping in Strait of Hormuz
- The real reason Meta shares are surging has nothing to do with its new AI model
- Stifel lifts Shopify to Buy, sees agentic commerce as next growth catalyst
- Delta Air Lines stock climbs on earnings beat and strong guidance
- Former emir of Qatar, Sheikh Hamad bin Khalifa Al Thani, dies at 74
- Almonty Industries (ALM) PT Raised to $33 at DA Davidson
- JPMorgan analysts name top short ideas for third quarter 2026
- The real reason Meta shares are surging has nothing to do with its new AI model
- Apple sues OpenAI, two former employees for trade secrets theft
Cowen Starts Avalanche Biotechnologies (AAVL) at Outperform
August 25, 2014 7:11 AM EDTCowen initiated coverage on Avalanche Biotechnologies (NASDAQ: AAVL) with an Outperform rating and a price target of $45.00.
For an analyst ratings summary and ratings history on Avalanche Biotechnologies click here. For more ratings news on Avalanche Biotechnologies click here.
Shares of Avalanche Biotechnologies closed at $30.52 yesterday.
... MoreJefferies Starts Avalanche Biotechnologies (AAVL) at Buy
August 25, 2014 6:55 AM EDTJefferies initiates coverage on July IPO Avalanche Biotechnologies (NASDAQ: AAVL) with a Buy rating and a price target of $40.00.
Analyst Biren Amin said, "AAVL shares hold significant promise based on PI data with AVA-101 observing meaningful VA improvements and durable responses in wAMD... More
Piper Jaffray Starts Avalanche Biotechnologies (AAVL) at Overweight
August 25, 2014 6:53 AM EDTPiper Jaffray initiates coverage on July IPO Avalanche Biotechnologies (NASDAQ: AAVL) with a Overweight rating and a price target of $39.00.
Analyst Joshua Schimmer comments, "The company is among a handful of pioneers in the gene therapy field, and a leader among an even... More
